ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 102,33
0,13%
Dow Jones
39 065,26
-1,53%
DAX
18 691,32
0,05%
Brent Oil
81,31
-0,27%
Bitcoin
67 613,24
-2,16%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Prelude Therapeutics Inc (PRLD)

  7. Prelude Therapeutics Inc (PRLD) Actualités

PRLD

Prelude Therapeutics (PRLD)

Prelude Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PRLD
DateHeureSourceTitreSymboleSociété
16/05/202422h09Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
16/05/202422h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
09/05/202413h01GlobeNewswire Inc.Prelude Therapeutics to Participate in Citizens JMP Life Sciences ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
09/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRLDPrelude Therapeutics Inc
07/05/202413h20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
07/05/202413h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
07/05/202413h01GlobeNewswire Inc.Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
06/05/202422h24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
09/04/202422h35GlobeNewswire Inc.Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
05/03/202422h45GlobeNewswire Inc.Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
29/02/202422h05GlobeNewswire Inc.Prelude Therapeutics to Participate in Barclays Global Healthcare ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
15/02/202423h22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRLDPrelude Therapeutics Inc
15/02/202422h05GlobeNewswire Inc.Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024NASDAQ:PRLDPrelude Therapeutics Inc
12/02/202422h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
11/12/202315h34GlobeNewswire Inc.Prelude Therapeutics Announces $25 Million Private PlacementNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202321h10GlobeNewswire Inc.Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ResultsNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202321h05Business WirePrelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:PRLDPrelude Therapeutics Inc
14/10/202318h30GlobeNewswire Inc.Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference NASDAQ:PRLDPrelude Therapeutics Inc
29/08/202314h30GlobeNewswire Inc.Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberNASDAQ:PRLDPrelude Therapeutics Inc
03/08/202314h00GlobeNewswire Inc.Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
21/06/202322h17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PRLDPrelude Therapeutics Inc
21/06/202322h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PRLDPrelude Therapeutics Inc
31/05/202314h30GlobeNewswire Inc.Prelude Therapeutics To Participate in Jefferies Healthcare ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
24/05/202322h55Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:PRLDPrelude Therapeutics Inc
18/05/202313h00GlobeNewswire Inc.Prelude Therapeutics Announces Pricing of Public OfferingNASDAQ:PRLDPrelude Therapeutics Inc
17/05/202322h08GlobeNewswire Inc.Prelude Therapeutics Announces Launch of Proposed Public OfferingNASDAQ:PRLDPrelude Therapeutics Inc
08/05/202314h30GlobeNewswire Inc.Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations UpdateNASDAQ:PRLDPrelude Therapeutics Inc
08/05/202314h12Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PRLDPrelude Therapeutics Inc
28/04/202315h47Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:PRLDPrelude Therapeutics Inc
28/04/202315h42Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PRLDPrelude Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PRLD

Dernières Valeurs Consultées

BOV
VIVR12
VIVER
COIN
ZOOMERUSD
ZOOMER
BOV
WHRL3M
WHIRLPOOL ON
BITMOT
2820533
Esm Fx 1% Jun27 Eur
COIN
KUBBTC
kublaicoin
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés